Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Hiroyuki Sakamaki is active.

Publication


Featured researches published by Hiroyuki Sakamaki.


Human Immunology | 2002

Genetic association between interleukin-10 gene promoter region polymorphisms and type 1 diabetes age-at-onset

Akane Ide; Eiji Kawasaki; Norio Abiru; Fuyan Sun; Ryoko Takahashi; Hironaga Kuwahara; Naruhiro Fujita; Atsushi Kita; Katsuya Oshima; Hiroyuki Sakamaki; Shigeo Uotani; Hironori Yamasaki; Yoshihiko Yamaguchi; Katsumi Eguchi

This study investigated whether interleukin-10 (IL-10) gene promoter region polymorphisms are associated with susceptibility to or clinical presentation of type 1 diabetes. The frequency of -1082G/A, -819C/T, and -592C/A polymorphisms was analyzed in 128 Japanese patients with type 1 diabetes and in 107 healthy control subjects in a case-controlled study. The allelic and haplotypic frequencies of the IL-10 gene promoter region polymorphisms were similar in patients with type 1 diabetes and in control subjects. However, the -819T and -592A allele were associated with adult-onset (>18 years) of the disease (p = 0.037). Furthermore, the frequency of ATA haplotype was increased in adult-onset patients than that in early-onset patients (< or =18 years; p = 0.037). Among the genotypes comprising ATA haplotype, the frequency of ATA/ATA was significantly higher in adult-onset patients than in early-onset patients (p = 0.004). These results suggest that the IL-10 gene promoter polymorphisms are associated with the age-at-onset in Japanese patients with type 1 diabetes.


Diabetes Research and Clinical Practice | 1999

CTLA4 gene polymorphism correlates with the mode of onset and presence of ICA512 Ab in Japanese Type 1 diabetes

Takahiro Abe; Hirofumi Takino; Hironori Yamasaki; Masako Ozaki; Yasunori Sera; Hideaki Kondo; Hiroyuki Sakamaki; Eiji Kawasaki; Takuya Awata; Yoshihiko Yamaguchi; Katsumi Eguchi

Recently, the association of CTLA4 gene polymorphism with type 1 diabetes and AITD has been reported in several populations. CTLA4 was originally reported to regulate T-cell activity and T-B cognate interaction. To investigate the role of CTLA4 in autoimmune diseases, we examined the correlation between CTLA4 gene polymorphism and the clinical characteristics of Japanese patients with type 1 diabetes, including the mode of onset of diabetes and presence of islet-specific autoantibodies (GAD, ICA 512 Ab) in the serum. We studied 111 patients with type 1 diabetes and 445 normal subjects. CTLA4 exon 1 position 49 (A/G: codon 17: Thr/Ala) polymorphism was defined, employing PCR-RFLP. Sixty-three (57%) patients had AITD. The allele frequencies of G and A in both 111 patients (G: 65%; A: 35%) and 63 patients (G: 62%; A: 38%) were not significantly different from the control subjects (G: 63%; A: 37%). Serum samples of 69 patients were obtained within a year after onset and used for pancreas specific autoantibodies analysis. These samples were also used for further analysis between CTLA4 gene polymorphism and clinical characteristics. The allele frequencies of G and A in patients who presented with diabetic ketoacidosis (DK+) (G: 75%; A: 25%) were significantly different from those in DK- patients (G: 50%, A: 50%, P = 0.003). Allele and genotype analyses showed significant differences between DK+ patients and control subjects (P = 0.014, P = 0.046, respectively). Allele frequencies of G and A were not significant between patients who were positive and negative for GAD Ab, but significant for ICA 512 Ab (G: 83%, A:17% versus G: 59%, A: 41%: positive patients versus negative patients, P = 0.004). Our results showed a significant correlation between CTLA4 gene polymorphism and ICA 512 Ab. Our results also indicated that CTLA4 gene polymorphism is associated with the onset mode of Japanese type 1 diabetes and the presence of ICA512 Ab. Further analysis of this polymorphism is necessary to fully understand the pathogenesis and progression of type 1 diabetes.


Experimental Biology and Medicine | 2003

Intracerebroventricular Administration of Insulin and Glucose Inhibits the Anorectic Action of Leptin in Rats

Naruhiro Fujita; Hiroyuki Sakamaki; Shigeo Uotani; Ryoko Takahashi; Hironaga Kuwahara; Atsushi Kita; Katsuya Oshima; Hironori Yamasaki; Yoshihiko Yamaguchi; Katsumi Eguchi

Obese individuals with glucose intolerance present with high serum levels of glucose, insulin, and leptin. These substances are potent inhibitors of feeding in the brain. Obese subjects still present with over-feeding despite elevation of the above factors. To elucidate the mechanism of this paradox, the effects of insulin and glucose on the anorectic action of leptin in the hypothalamus were examined. Adult male Sprague-Dawley rats (weighing 2850–320 g) were pretreated with intracerebroventricular injection of insulin, glucose, or saline, followed by leptin (7.5 μg) or phosphate-buffered saline (PBS) injection into the third cerebral ventricle (icv). The cumulative food intakes were measured 24 hr after leptin icv. The tyrosine phosphorylation of signal transducer and activator transcription factor 3 (STAT3) in the hypothalamus was determined by Western blotting. In rats pretreated with saline and stimulated with leptin (saline/LEPTIN group), food intake diminished to about 50% of that of the saline/PBS group (P < 0.005). Food intake in the insulin/LEPTIN group was significantly higher compared with the saline/LEPTIN group (P < 0.005) and reached the level seen in the saline/PBS group. Similar data were obtained in glucose pretreatment experiments. Insulin and glucose icv resulted in reduction of leptin-induced STAT3 tyrosine phosphorylation compared with saline. Infusion of insulin and glucose icv did not alter peripheral blood glucose levels in all groups. High insulin or glucose levels in the brain could result in leptin resistance as manifested by food intake, which is probably due to the attenuation of STAT3 phosphorylation downstream the leptin receptor.


Diabetic Medicine | 1998

No deterioration in insulin sensitivity, but impairment of both pancreatic β-cell function and glucose sensitivity, in Japanese women with former gestational diabetes mellitus

Hiroyuki Sakamaki; Hironori Yamasaki; K. Matsumoto; K. Izumino; Hideaki Kondo; Yasunori Sera; Masako Ozaki; Takahiro Abe; Eiji Kawasaki; Hirofumi Takino; Yoshihiko Yamaguchi; Katsumi Eguchi

To identify the primary pathogenic factors involved in the development of Type 2 diabetes mellitus (DM), we studied Japanese women with former gestational diabetes mellitus (GDM) who are at risk for the later development of Type 2 DM. We used the minimal model analysis derived from frequently sampled intravenous glucose tolerance test (FSIGT). The subjects consisted of eight non‐obese women with a history of GDM and eight non‐obese normal women as control subjects. The 75 g oral glucose tolerance test (75 g OGTT) performed within 6 months of delivery confirmed that all the subjects with former GDM had a normal glucose tolerance. Insulin sensitivity (SI) derived from the minimal model analysis was not different between the two groups. Glucose effectiveness at zero insulin (GEZI), reflecting tissue glucose sensitivity, was significantly lower in former GDM patients than in control subjects (1.18 ± 0.34 vs 2.26 ± 0.29 × 10−2 min−1, p < 0.05). The early phase insulin secretion found in FSIGT was markedly reduced to 56 % of that observed in control subjects (1250 ± 187.4 vs 2223 ± 304.3 pmol l−1 min, p < 0.01). Our results indicate that in former GDM patients, who are Japanese and non‐obese, impairment of the acute insulin response to glucose and a decrease in tissue glucose sensitivity rather than insulin sensitivity are the primary pathogenic factors involved. Copyright


Molecular and Cellular Endocrinology | 2003

Insulin attenuates leptin-induced STAT3 tyrosine-phosphorylation in a hepatoma cell line

Hironaga Kuwahara; Shigeo Uotani; Takahiro Abe; Mikako Degawa-Yamauchi; Ryoko Takahashi; Atsushi Kita; Naruhiro Fujita; Katuya Ohshima; Hiroyuki Sakamaki; Hironori Yamasaki; Yoshihiko Yamaguchi; Katsumi Eguchi

Leptin, the 16 kDa protein product of the ob gene, is secreted by adipocytes. The long form leptin receptor (ObRb) is expressed at high levels in the hypothalamus, and regulates appetite and energy expenditure. The fact that serum concentration of leptin is correlated with body mass index (BMI) suggests reduced sensitivity to leptin. Even though hyperinsulinemia and hyperleptinemia could coexist in obese humans, little is known about the interaction of insulin and leptin. In this study, we examined the effect of insulin on leptin signaling using Huh 7 cells transiently transfected with ObRb cDNA. Insulin inhibits leptin-induced STAT3 phosphorylation in a time- and dose-dependent manner without affecting Janus tyrosine kinases (JAKs) JAK2 phosphorylation. Okadaic acid prevents the inhibitory effect of insulin on leptin-induced STAT3 activation.


The Journal of Clinical Endocrinology and Metabolism | 1996

High-dose but not low-dose dexamethasone impairs glucose tolerance by inducing compensatory failure of pancreatic beta-cells in normal men.

Kazunari Matsumoto; Hironori Yamasaki; Shoichi Akazawa; Hiroyuki Sakamaki; Miwa Ishibashi; Norio Abiru; Shigeo Uotani; Hiroshi Matsuo; Yoshihiko Yamaguchi; K Tokuyama; S. Nagataki


Free Radical Biology and Medicine | 1997

Oxygen-Induced Embryopathy and the Significance of Glutathione-Dependent Antioxidant System in the Rat Embryo During Early Organogenesis

Miwa Ishibashi; Shoichi Akazawa; Hiroyuki Sakamaki; Kazunari Matsumoto; Hironori Yamasaki; Yoshihiko Yamaguchi; Shinji Goto; Yoshishige Urata; Takahito Kondo; Shigenobu Nagataki


Journal of Biological Chemistry | 2004

Rapid Inhibition of Leptin Signaling by Glucocorticoids in Vitro and in Vivo

Ryoko Ishida-Takahashi; Shigeo Uotani; Takahiro Abe; Mikako Degawa-Yamauchi; Tetsuya Fukushima; Naruhiro Fujita; Hiroyuki Sakamaki; Hironori Yamasaki; Yoshihiko Yamaguchi; Katsumi Eguchi


The Journal of Clinical Endocrinology and Metabolism | 1997

Troglitazone ameliorates insulin resistance in patients with Werner's syndrome.

Kiyohiro Izumino; Hiroyuki Sakamaki; Miwa Ishibashi; Hirofumi Takino; Hironori Yamasaki; Yoshihiko Yamaguchi; Nobuhiro Chikuba; Kazunari Matsumoto; Shoichi Akazawa; Shigenobu Nagataki


Metabolism-clinical and Experimental | 2000

Increased insulin sensitivity and decreased insulin secretion in offspring of insulin-sensitive type 2 diabetic patients.

Kazunari Matsumoto; Hiroyuki Sakamaki; Kiyohiro Izumino; Mayumi Yano; Yukitaka Ueki; Seibei Miyake; Yuko Tominaga

Collaboration


Dive into the Hiroyuki Sakamaki's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Shigeo Uotani

Beth Israel Deaconess Medical Center

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge